Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Exelixis Inc(EXEL)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for EXEL
10/23/2026: EXEL (4-star) is a STRONG-BUY. BUY for 37 days. Simulated Profits (10.25%). Updated daily EoD!
Exelixis is a specialized biotechnology company focused on developing small-molecule cancer therapies, anchored by the commercial success of its flagship drug, CABOMETYX. The company has a stable financial profile with strong margins and significant cash reserves to fund R&D. Its primary growth story revolves around successfully evolving its pipeline, particularly with the next-generation asset zanzalintinib, to reduce its dependence on the cabozantinib franchise. Key risks include intense market competition, patent exposure, and the inherent uncertainty of clinical trials. The stock may best suit growth-oriented investors with an appetite for biotech-specific volatility and a willingness to monitor clinical trial readouts for material catalysts.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company is transitioning from a high-growth phase to a more mature commercial stage, making future growth dependent on pipeline success. |
| Momentum investor | Strong fit while signal remains positive | Momentum interest is typically driven by clinical data catalysts and trial results. |
| Value investor | Mixed fit | The valuation is often tied to future pipeline potential, making it difficult to assess using traditional value metrics. |
| Dividend investor | Weak fit | Exelixis does not pay a dividend, making it unsuitable for income-focused portfolios. |
| Low-risk investor | Weak fit | The reliance on a narrow product portfolio and the binary nature of clinical trials create significant volatility. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is highly sensitive to clinical trial announcements and regulatory decisions. |
| Valuation risk | Medium | Market sentiment frequently shifts based on expectations for the next-generation pipeline. |
| Competition risk (Oncology/Kinase Inhibitors) | High | The competitive landscape for solid tumor treatments is crowded with better-capitalized peers. |
| Business quality | Medium | While the company has strong margins, its business quality is tempered by product concentration. |
| Dividend income | Low / none | No dividend is paid to shareholders. |
| Execution risk | Medium / high | Successfully bringing new molecules through late-stage trials is notoriously difficult and risky. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit 29.91% | Avg. Invested days 41 | Today’s Advisory Regular Buy |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/23/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 15.99B USD | Price to earnings Ratio 20.36 | 1Y Target Price 55.53 |
Price to earnings Ratio 20.36 | 1Y Target Price 55.53 | ||
Volume (30-day avg) 2.2M shares | Beta 0.47 | 52 Weeks Range 36.00 - 65.50 | Updated Date 10/24/2026 |
52 Weeks Range 36.00 - 65.50 | Updated Date 10/24/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 3.17 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Product Sales | Revenue generated from the sale of CABOMETYX and COMETRIQ in the US and international markets. | The vast majority of money comes from sales of their primary cancer drug, CABOMETYX. |
| Collaboration Revenue | Milestone payments and royalties from collaborative partnerships. | Additional revenue is generated when partner companies hit specific development or sales milestones. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-10-29 | When After Market | Estimate 0.79 | Actual - |
Profitability
Profit Margin 35.33% | Operating Margin (TTM) 39.51% |
Management Effectiveness
Return on Assets (TTM) 23.97% | Return on Equity (TTM) 44.39% |
Valuation
Trailing PE 20.36 | Forward PE 13.55 | Enterprise Value 13.82B | Price to Sales(TTM) 6.56 |
Enterprise Value 13.82B | Price to Sales(TTM) 6.56 | ||
Enterprise Value to Revenue 5.64 | Enterprise Value to EBITDA 13.46 | Shares Outstanding 247.78M | Shares Floating 213.60M |
Shares Outstanding 247.78M | Shares Floating 213.60M | ||
Percent Insiders 1.85 | Percent Institutions 106.94 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.